Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycerophosphodiester phosphodiesterase domain-containing protein 1 (GDPD1) is a member of the glycerophosphodiester phosphodiesterase family of enzymes. It hydrolyzes deacylated glycerophospholipids, specifically lysoglycerophospholipids, to yield lysophosphatidic acid (LPA) and corresponding amines, playing a role in glycerol metabolism and lipid remodeling[2][5][1]. If additional structured data is needed—such as approved drugs, biomarkers, or clear disease roles—there is currently no strong evidence of these from the provided sources, indicating this protein is mainly recognized for its biochemical activity as an enzyme and not yet a major therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycerophosphodiester phosphodiesterase domain-containing protein 1 (GDPD1).